Combigene AB (COMBI) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.087x

Based on the latest financial reports, Combigene AB (COMBI) has a cash flow conversion efficiency ratio of -0.087x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.23 Million ≈ $-670.56K USD) by net assets (Skr71.58 Million ≈ $7.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Combigene AB worth for the company's overall valuation and market capitalisation.

Combigene AB - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Combigene AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Combigene AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Combigene AB ranked by their cash flow conversion efficiency. Explore Combigene AB earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
VIA OPTRONICS AG SP.ADS/1 F:5UU1	N/A
Tribe Property Technologies Inc V:TRBE	-0.229x
SOLAI Limited NYSE:SLAI	-0.355x
ACG Acquisition Co. Ltd. LSE:ACG	0.494x
Wickes Group PLC LSE:WIX	1.293x
Exact Therapeutics AS OL:EXTX	-0.697x
First Venture Sweden AB Series B ST:FIRST-B	-0.027x
Ahlada Engineers Limited NSE:AHLADA	0.024x

Annual Cash Flow Conversion Efficiency for Combigene AB (2012–2024)

The table below shows the annual cash flow conversion efficiency of Combigene AB from 2012 to 2024. View Combigene AB share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Combigene AB

ST:COMBI Sweden Biotechnology

Market Cap

$5.24 Million

Skr48.71 Million SEK

Market Cap Rank

#28582 Global

#638 in Sweden

Share Price

Skr2.46

Change (1 day)

+0.00%

52-Week Range

Skr2.46 - Skr2.46

All Time High

Skr152.75